Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OC701
- Development stage
- Preclinical
- Lead developer
- Oncocross
- Modality
- Small Molecules
01
Overview
OC701 is a preclinical-stage small molecule drug candidate being developed by Oncocross Australia, a subsidiary of the AI-powered biotechnology company OnCoCross. Discovered using the proprietary RAPTOR AI™ platform—which analyzes transcriptomic data to identify novel drug-disease associations—OC701 is intended for the treatment of atopic dermatitis. As of early 2024, the candidate is in the in vitro/in vivo preclinical testing stage, with specific molecular targets remaining confidential. The development of OC701 aligns with Oncocross's focus on utilizing AI to streamline the discovery of treatments for intractable and rare diseases.
Beyond the preview
Go deeper on OC701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OC701.